These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 39226482)
1. Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation. Sun W; Zhang H; Xie W; Ma L; Dang Y; Liu Y; Li L; Qu F; Tan W J Am Chem Soc; 2024 Sep; 146(37):25490-25500. PubMed ID: 39226482 [TBL] [Abstract][Full Text] [Related]
2. Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes. Miao Y; Gao Q; Mao M; Zhang C; Yang L; Yang Y; Han D Angew Chem Int Ed Engl; 2021 May; 60(20):11267-11271. PubMed ID: 33634555 [TBL] [Abstract][Full Text] [Related]
3. Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis. Zhou P; Zhang S; Li L; Zhang R; Guo G; Zhang Y; Wang R; Liu M; Wang Z; Zhao H; Yang G; Xie S; Ran J Theranostics; 2024; 14(13):4983-5000. PubMed ID: 39267779 [No Abstract] [Full Text] [Related]
4. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. Wu Y; Lin B; Lu Y; Li L; Deng K; Zhang S; Zhang H; Yang C; Zhu Z Angew Chem Int Ed Engl; 2023 Apr; 62(15):e202218106. PubMed ID: 36722696 [TBL] [Abstract][Full Text] [Related]
6. Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface. Duan Q; Jia HR; Chen W; Qin C; Zhang K; Jia F; Fu T; Wei Y; Fan M; Wu Q; Tan W Adv Sci (Weinh); 2024 May; 11(17):e2308924. PubMed ID: 38425146 [TBL] [Abstract][Full Text] [Related]
7. LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins. Ramadas B; Kumar Pain P; Manna D ChemMedChem; 2021 Oct; 16(19):2951-2953. PubMed ID: 34296796 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Su LY; Tian Y; Zheng Q; Cao Y; Yao M; Wang S; Xu W; Xi C; Clocchiatti A; Nie G; Zhou H Cell Chem Biol; 2024 Jun; 31(6):1219-1230.e5. PubMed ID: 38309277 [TBL] [Abstract][Full Text] [Related]
9. Programming DNA Nanoassemblies into Polyvalent Lysosomal Degraders for Potent Degradation of Pathogenic Membrane Proteins. Yu S; Shi T; Li C; Xie C; Wang F; Liu X Nano Lett; 2024 Sep; 24(37):11573-11580. PubMed ID: 39225423 [TBL] [Abstract][Full Text] [Related]
10. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma. Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139 [TBL] [Abstract][Full Text] [Related]
11. Repurposing AS1411 for constructing ANM-PROTACs. Fu X; Li J; Chen X; Chen H; Wang Z; Qiu F; Xie D; Huang J; Yue S; Cao C; Liang Y; Lu A; Liang C Cell Chem Biol; 2024 Jul; 31(7):1290-1304.e7. PubMed ID: 38657608 [TBL] [Abstract][Full Text] [Related]
12. Antitumor Effect of Anti-c-Myc Aptamer-Based PROTAC for Degradation of the c-Myc Protein. Wang Y; Yang G; Zhang X; Bai R; Yuan D; Gao D; He Q; Yuan Y; Zhang X; Kou J; Zheng L; Huang Y; Tang Z; Bao Y; Song X; Zhao Y Adv Sci (Weinh); 2024 Jul; 11(26):e2309639. PubMed ID: 38682443 [TBL] [Abstract][Full Text] [Related]
13. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Ahn G; Riley NM; Kamber RA; Wisnovsky S; Moncayo von Hase S; Bassik MC; Banik SM; Bertozzi CR Science; 2023 Oct; 382(6668):eadf6249. PubMed ID: 37856615 [TBL] [Abstract][Full Text] [Related]
14. Polyfluoroalkyl Tag Decoration Enables Significantly Enhanced Tumor Penetration Ability of a PTK7 Targeting Aptamer. Li Y; Zhang C; Fu T; Wang XQ; Tan W Bioconjug Chem; 2024 May; 35(5):674-681. PubMed ID: 38695582 [TBL] [Abstract][Full Text] [Related]
15. Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Ahn G; Banik SM; Bertozzi CR Cell Chem Biol; 2021 Jul; 28(7):1072-1080. PubMed ID: 33770486 [TBL] [Abstract][Full Text] [Related]
16. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like Growth Factor 2 (IGF2)-Fused Lysosomal Targeting Chimeras for Degradation of Extracellular and Membrane Proteins. Zhang B; Brahma RK; Zhu L; Feng J; Hu S; Qian L; Du S; Yao SQ; Ge J J Am Chem Soc; 2023 Nov; 145(44):24272-24283. PubMed ID: 37899626 [TBL] [Abstract][Full Text] [Related]
18. An Intelligent DNA Nanorobot with Ma W; Zhan Y; Zhang Y; Shao X; Xie X; Mao C; Cui W; Li Q; Shi J; Li J; Fan C; Lin Y Nano Lett; 2019 Jul; 19(7):4505-4517. PubMed ID: 31185573 [TBL] [Abstract][Full Text] [Related]
20. Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept. Calzada V; Moreno M; Newton J; González J; Fernández M; Gambini JP; Ibarra M; Chabalgoity A; Deutscher S; Quinn T; Cabral P; Cerecetto H Bioorg Med Chem; 2017 Feb; 25(3):1163-1171. PubMed ID: 28089349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]